The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 969-983

  Parikh, Rahul A ^a   Wang, Peng ^b   Beumer, Jan H ^a   Chu, Edward ^a   Appleman, Leonard J ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Cancer; HGF inhibitor; MET inhibitor

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ADENOSINE TRIPHOSPHATE; AMG 458; BAY 853474; BIOLOGICAL MARKER; CABOZANTINIB; CRIZOTINIB; FICLATUZUMAB; FORETINIB; K RAS PROTEIN; METMAB; MK 2461; ONARTUZUMAB; PF 04217903; PROTEIN TYROSINE KINASE INHIBITOR; RILOTUMUMAB; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TIVANTINIB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; DRUG RESPONSE; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE TRANSLOCATION; GROWTH INHIBITION; HUMAN; INTRACELLULAR SIGNALING; MET GENE; NONHUMAN; ONCOGENE K RAS; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POINT MUTATION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; PROTO ONCOGENE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; UPREGULATION;

EID: 84902313522     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S40241     Document Type: Review

References (101)

1. Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun. 1984;122(3):1450-1459.
2. Michalopoulos G, Houck KA, Dolan ML, Leutteke NC. Control of hepatocyte replication by two serum factors. Cancer Res. 1984;44(10): 4414-4419.
3. Russell WE, McGowan JA, Bucher NL. Partial characterization of a hepatocyte growth factor from rat platelets. J Cell Physiol. 1984;119(2): 183-192.
4. Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989;342(6248): 440-443.
5. Naldini L, Weidner KM, Vigna E, et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J. 1991;10(10):2867-2878.
6. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991;251(4995):802-804.
7. Boccaccio C, Andò M, Tamagnone L, et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature. 1998;391(6664):285-288.
8. Schmidt C, Bladt F, Goedecke S, et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature. 1995;373(6516): 699-702.
9. Uehara Y, Minowa O, Mori C, et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature. 1995;373(6516):702-705.
10. Tsarfaty I, Rong S, Resau JH, Rulong S, da Silva PP, Vande Woude GF. The Met proto-oncogene mesenchymal to epithelial cell conversion. Science. 1994;263(5143):98-101.
11. Cooper CS, Tempest PR, Beckman MP, Heldin CH, Brookes P. Amplifcation and overexpression of the met gene in spontaneously transformed NIH3T3 mouse fibroblasts. EMBO J. 1986;5(10): 2623-2628.
12. Di Renzo MF, Narsimhan RP, Olivero M, et al. Expression of the Met/ HGF receptor in normal and neoplastic human tissues. Oncogene. 1991;6(11):1997-2003.
13. Takayama H, LaRochelle WJ, Sharp R, et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepato-cyte growth factor/scatter factor. Proc Natl Acad Sci U S A. 1997;94(2): 701-706.
14. Ma PC, Kijima T, Maulik G, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 2003;63(19):6272-6281.
15. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16(1):68-73.
16. Wallenius V, Hisaoka M, Helou K, et al. Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors. Am J Pathol. 2000;156(3):821-829.
17. Kijima Y, Hokita S, Yoshinaka H, et al. Amplifcation and overexpres-sion of c-met gene in Epstein-Barr virus-associated gastric carcinomas. Oncology. 2002;62(1):60-65.
18. Soman NR, Wogan GN, Rhim JS. TPR-MET oncogenic rearrangement: detection by polymerase chain reaction amplifcation of the transcript and expression in human tumor cell lines. Proc Natl Acad Sci U S A. 1990;87(2):738-742.
19. Soman NR, Correa P, Ruiz BA, Wogan GN. The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. Proc Natl Acad Sci U S A. 1991;88(11): 4892-4896.
20. Kentsis A, Reed C, Rice KL, et al. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med. 2012;18(7):1118-1122.
21. Lorenzato A, Olivero M, Patanè S, et al. Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Res. 2002;62(23):7025-7030.
22. Zeng ZS, Weiser MR, Kuntz E, et al. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett. 2008;265(2):258-269.
23. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplifca-tion leads to geftinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316(5827):1039-1043.
24. Yano S, Wang W, Li Q, et al. Hepatocyte growth factor induces geftinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 2008;68(22): 9479-9487.
25. Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487(7408):500-504.
26. Chen CT, Kim H, Liska D, Gao S, Christensen JG, Weiser MR. MET activation mediates resistance to lapatinib inhibition of HER2-amplifed gastric cancer cells. Mol Cancer Ther. 2012;11(3):660-669.
27. Grugan KD, Miller CG, Ya o Y, et al. Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal squamous cell carcinoma invasion. Proc Natl Acad Sci U S A. 2010;107(24):11026-11031.
28. Lennerz JK, Kwak EL, Ackerman A, et al. MET amplifcation identifes a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011; 29(36):4803-4810.
29. Hwang CI, Matoso A, Corney DC, et al. Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci U S A. 2011;108(34):14240-14245.
30. Qian F, Engst S, Yamaguchi K, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res. 2009;69(20):8009-8016.
31. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 2009;15(7):2207-2214.
32. Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013;31(2): 181-186.
33. Posadas EM, Figlin RA. Understanding the role of MET kinase in cancer therapy. J Clin Oncol. 2013;31(2):169-170.
34. Shah MA, Wainberg ZA, Catenacci DV, et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/ VEGFR2 inhibitor, in patients with metastatic gastric cancer. PloS One. 2013;8(3):e54014.
35. Christensen JG, Schreck R, Burrows J, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 2003;63(21):7345-7355.
36. Smolen GA, Sordella R, Muir B, et al. Amplifcation of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A. 2006;103(7):2316-2321.
37. Zopf DK, Kissel M, Mamounas M, et al. The novel highly selective and effcacious MET inhibitor BAY853474: mode of action, basic in vitro characteristics and preclinical pharmacology. EJC Supplements. 2010;8(7):53-54.
38. Klotz M, Schmid E, Steiner-Hahn K, et al. Preclinical evaluation of biomarkers for response monitoring to the MET inhibitor BAY-853474. Biomarkers. 2012;17(4):325-335.
39. Pan BS, Chan GK, Chenard M, et al. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010;70(4):1524-1533.
40. Liu L, Norman MH, Lee M, et al. Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profles of the pyrazolone series. J Med Chem. 2012;55(5):1868-1897.
41. Liu L, Siegmund A, Xi N, et al. Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-meth yl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458). J Med Chem. 2008;51(13):3688-3691.
42. Cui JJ, McTigue M, Nambu M, et al. Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identifcation of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1 -yl)ethanol (PF-04217903) for the treatment of cancer. J Med Chem. 2012;55(18):8091-8109.
43. Zou HY, Li Q, Lee JH, et al. Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor. Mol Cancer Ther. 2012;11(4):1036-1047.
44. Munshi N, Jeay S, Li Y, et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther. 2010;9(6):1544-1553.
45. Eathiraj S, Palma R, Volckova E, et al. Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J Biol Chem. 2011;286(23): 20666-20676.
46. Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 phar-macogenetics and cancer. Oncogene. 2006;25(11):1679-1691.
47. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical signifcance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41(12):913-958.
48. Rosen LS, Senzer N, Mekhail T, et al. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res. 2011;17(24):7754-7764.
49. Goldman JW, Laux I, Chai F, et al. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer. 2012;118(23):5903-5911.
50. Ya p TA, Olmos D, Brunetto AT, et al. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacody-namic studies. J Clin Oncol. 2011;29(10):1271-1279.
51. Wagner AJ, Goldberg JM, Dubois SG, et al. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer. 2012;118(23):5894-5902.
52. Sequist LV, von Pawel J, Garmey EG, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol. 2011;29(24): 3307-3315.
53. Scagliotti GV, Novello S, Schiller JH, et al. Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. Clin Lung Cancer. 2012;13(5):391-395.
54. Basilico C, Pennacchietti S, Vigna E, et al. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. Clin Cancer Res. 2013;19(9):2381-2392.
55. Katayama R, Aoyama A, Yamori T, et al. Cytotoxic activity of tivan-tinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res. 2013;73(10):3087-3096.
56. Michieli P, Di Nicolantonio F. Targeted therapies: Tivantinib - a cytotoxic drug in MET inhibitor's clothes? Nat Rev Clin Oncol. 2013; 10(7):372-374.
57. Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogen-esis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298-2308.
58. Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011;29(19):2660-2666.
59. Schoffski P, Elisei R, Müller S, et al; EXAM Study Group. An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. J Clin Oncol. 2012;30(Suppl; abstr 5508).
60. Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in Patients with Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial. J Clin Oncol. 2013;31(4):412-419.
61. Cometriq (Cabozantinib) [FDA package insert]. South San Francisco, CA: Exelixis; 2013.
62. Winer EP, Tolaney S, Nechushtan H, et al. Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT). J Clin Oncol (Meeting Abstracts). 2012;30(Suppl 535).
63. Gordon MS, Kluger HM, Shapiro G, et al. Activity of cabozantinib (XL184) in metastatic melanoma: Results from a phase II randomized discontinuation trial (RDT). J Clin Oncol (Meeting Abstracts). 2012;30(Suppl 8531)
64. Verslype C, Cohn AL, Kelley RK, et al. Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT). J Clin Oncol (Meeting Abstracts). 2012;30(Suppl 4007).
65. Choueiri TK, Pal SK, McDermott DF, et al. Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC). J Clin Oncol (Meeting Abstracts). 2012;30(Suppl 4504).
66. Hellerstedt BA, Edelman G, Vogelzang NJ, et al. Activity of cabozan-tinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT). J Clin Oncol (Meeting Abstracts). 2012;30(Suppl 7514).
67. Buckanovich RJ, Berger R, Sella A et al. Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT). J Clin Oncol (Meeting Abstracts). 2011;29(Suppl 5008).
68. Apolo AB, Parnes HL, Madan RA, et al. A phase II study of cabozan-tinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC). J Clin Oncol (Meeting Abstracts). 2014;32(Suppl 4:307)
69. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor effcacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007;67(9):4408-4417.
70. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18): 1693-1703.
71. Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplifcation. J Thorac Oncol. 2011;6(5):942-946.
72. Jun HT, Sun J, Rex K, et al. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the effcacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res. 2007;13(22 Pt 1):6735-6742.
73. Gordon MS, Sweeney CS, Mendelson DS, et al. Safety, pharmacoki-netics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a frst-in-human study of patients with advanced solid tumors. Clin Cancer Res. 2010;16(2):699-710.
74. Rosen PJ, Sweeney CJ, Park DJ, et al. A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. Clin Cancer Res. 2010;16(9):2677-2687.
75. Schöffski P, Garcia JA, Stadler WM, et al. A phase II study of the effcacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int. 2011;108(5):679-686.
76. Wen PY, Schiff D, Cloughesy TF, et al. A phase II study evaluating the effcacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol. 2011;13(4):437-446.
77. Ryan CJ, Rosenthal M, Ng S, et al. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Cancer Res. 2013;19(1):215-224.
78. Amgen. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG102) With Epirubicin, Cis-platin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma. Available from: http://clinicaltrials.gov/show/NCT01697072. NLM Identifer: NCT01697072. Accessed September 27, 2013.
79. Patnaik A, Weiss GJ, Papadopoulos K, et al. Phase I study of SCH 900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb), as a single agent and in combination with erlotinib (E) in patients (pts) with advanced solid tumors. J Clin Oncol. 2010; 28(Suppl; abstr 2525).
80. Tan EP, Park K, Lim WT, et al. Phase Ib study of fclatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with geftinib (G) in Asian patients (pts) with NSCLC. J Clin Oncol (Meeting Abstracts). 2011;29(15 Suppl 7571).
81. Mok TSK, Park K, Geater SL, et al. A randomized phase 2 study with exploratory biomarker analysis of fclatuzumab a humanized hepatocyte growth factor inhibitory MAB in combination with geftinib versus geftinib in Asian patients with lung adenocarcinoma. Ann Oncol. 2012;23(abstr 1198P).
82. Okamoto W, Okamoto I, Tanaka K, et al. TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses geftinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation. Mol Cancer Ther. 2010;9(10): 2785-2792.
83. Jones SF, Cohen RB, Bendell JC, et al. Safety, tolerability, and phar-macokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: First-in-human phase I dose-escalation study. J Clin Oncol. 2010;28(15 Suppl abstr 3081).
84. Merchant M, Ma X, Maun HR, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A. 2013;110(32): E2987-E2996.
85. Jin H, Yang R, Zheng Z, et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. C Cancer Res. 2008;68(11):4360-4368.
86. Spigel DR, Ervin TJ, Ramlau R, et al. Final effcacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol. 2011;29(Suppl; abstr 7505).
87. Spigel DR, Edelman MJ, Mok T, et al. The MetLUNG study: A randomized, double-blind, phase III study of onartuzumab (MetMAb) plus erlotinib versus placebo plus erlotinib in patients with advanced, MET-positive non-small cell lung cancer (NSCLC). J Clin Oncol. 2012;30(Suppl; abstr TPS7616).
88. Bendell JC, Ervin TJ, Gallinson D, et al. Treatment Rationale and Study Design for a Randomized, Double-Blind, Placebo-Controlled Phase II Study Evaluating Onartuzumab (MetMAb) in Combination With Bevacizumab Plus mFOLFOX-6 in Patients With Previously Untreated Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2013;12(3):218-222.
89. Matsubara D, Ishikawa S, Oguni S, Aburatani H, Fukayama M, Niki T. Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells. J Thorac Oncol. 2010;5(9):1317-1324.
90. Eng C, Van Cutsem E, Nowara A, et al. A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analyses. J Clin Oncol. 2011;29(Suppl; abstr 3500).
91. Yu W, Pandita A, Penuel E, et al. Exploratory biomarker analyses from OAM4558g: A placebo-controlled phase II study of erlotinib with or without MetMAb in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2011;29(Suppl; abstr 7529).
92. Rimassa LPC, Borbath I, Daniele B, et al. Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: Results of a randomized controlled phase II trial (RCT). J Clin Oncol. 2012;(Suppl; abstr 4006).
93. Muro KRM, Yasui H, Nishina T, et al. A phase II study of tivantinib monotherapy in patients with previously treated advanced or recurrent gastric cancer. J Clin Oncol. 2012;30(Suppl; abstr 4082).
94. Sadanandam A, Lyssiotis CA, Homicsko K, et al. A colorectal cancer classifcation system that associates cellular phenotype and responses to therapy. Nat Med. 2013;19(5):619-625.
95. Qi J, McTigue MA, Rogers A, et al. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res. 2011;71(3):1081-1091.
96. Lee N V, Lira ME, Pavlicek A, et al. A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells though MAPK activation. PloS One. 2012;7(6):e39653.
97. Diamond JR, Salgia R, Varella-Garcia M, et al. Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma. J Clin Oncol. 2013;31(16):e254-e258.
98. Bachleitner-Hofmann T, Sun MY, Chen CT, et al. Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplifed tumor cells with or without resistance to selective MET Inhibition. Clin Cancer Res. 2011;17(1):122-133.
99. Feldman DR, Einhorn LH, Quinn DI, et al. A phase 2 multi-center study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors. Invest New Drugs. 2013;31(4):1016-1022.
100. Santoro A, Rimassa L, Borbath I, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 2013;14(1):55-63.
101. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12(2): 89-103.